Suramin's development: What did we learn?

Investigational New Drugs

Volumn 20, Issue 2, 2002, Pages 209-219

  Kaur, Maninderjeet ^a   Reed, Eddie ^b   Sartor, Oliver ^b   Dahut, William ^c   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Prostate cancer; Suramin

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; SURAMIN;

ANEMIA; BLOOD CLOTTING DISORDER; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; KIDNEY DISEASE; LETHARGY; LIVER DISEASE; NEUROTOXICITY; NEUTROPENIA; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURAMIN; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 0036286634     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015666024386     Document Type: Review

References (53)

1. Suramin: A new therapeutic concept
2. Intravesical suramin: A novel agent for the treatment of superficial transitional-cell carcinoma of the bladder
3. Suramin
4. Effects of suramin on HTLV-III/1AV infection presenting as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo
5. Suramin therapy in AIDS and related disorders
6. New anticancer drugs in Europe
7. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: Compelling reasons for testing in patients with hormone refractory breast cancer
8. Suramin: A novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer
9. Suramin - An anticancer drug with a unique mechanism of action
10. Hormone-refractory (D3) prostate cancer: Refining the concept
11. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
12. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer
13. The treatment of hormone refractory prostate cancer
14. Suramin therapy for patients with symptomatic hormone refractory prostate cancer; results of a phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortsone
15. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
16. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
17. Tumor markers in prostate cancer
18. Tumour markers in prostatic carcinoma: A comparison of prostate specific antigens with acid phosphatase
19. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
20. A pharmacokinetically guided phase II study of carboxyamidotriazole in androgen-independent prostate cancer
21. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines
22. The control of prostate-specific antigen expression and gene regulation by pharmacological agents
23. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone refractory prostate cancer
24. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
25. Therapeutic options in patients with hormone-refractory prostate cancer
26. Suramin in hormone refractory metastatic prostate cancer: A drug with limited efficacy
27. Treatment of metastatic prostate cancer with low dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
28. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
29. Effect of prednisone on prostatespecific antigen in patients with hormone-refractory prostate cancer
30. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
31. Prospective evaluation of hydrocortisone and suramin in patient with androgen-independent prostate cancer
32. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer
33. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: Simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal
34. Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence
35. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
36. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer: A southwest oncology group study
37. Prognostic factors for survival of patients with bidimentionally measurable metastatic hormone refractory prostatic cancer treated with single-agent chemotherapy
38. Prognostic factor in metastatic and hormonally unresponsive carcinoma of the prostate
39. Suramin treatment in hormone- and chemotherapy-refractory prostate cancer
40. VEGF and Basic FGF urine levels as predictors of response to therapy with suramin in CALGB 9480, a phase III study of hormone refractory prostate cancer (HRPC) patients
41. Adaptive control with feedback strategies for suramin dosing
42. Recent research on the biological activity of suramin
43. Suramin
44. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin
45. Suramin-induced polyneuropathy
46. Results of CALB 9480, phase III trial of 3 different doses of suramin for the treatment of hormone refractory prostate cancer (HRPC)
47. Phase I and pharmacologic evaluation of a monthly, daily times five days (d), schedule (sch) of suramin (s) in patients (pts) with hormone refractory prostate cancer (hrpc)
48. Prostate-specific antigen (PSA) best practice policy
49. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: Toxicity and response
50. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients
51. Characterization of patients with androgenindependent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal
52. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin